Artivion, Inc. (AORT)
| Market Cap | 1.14B -44.6% |
| Revenue (ttm) | 471.47M +16.4% |
| Net Income | -3.19M |
| EPS | -0.07 |
| Shares Out | 48.76M |
| PE Ratio | n/a |
| Forward PE | 227.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 415,346 |
| Open | 23.86 |
| Previous Close | 23.97 |
| Day's Range | 22.91 - 24.20 |
| 52-Week Range | 19.16 - 48.25 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 40.91 (+75.58%) |
| Earnings Date | Nov 5, 2026 |
About AORT
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branc... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price target is $40.91, which is an increase of 75.58% from the latest price.
News
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
ATLANTA, Oct. 22, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results ...
Artivion initiated with a Buy at Jefferies
Jefferies initiated coverage of Artivion (AORT) with a Buy rating and $31 price target Artivion is a a play on aortic surgery with a “healthy cadence” of new product launches…
GraniteShares Announces Weekly Distributions for its YieldBOOST ETFs
New York, Aug. 20, 2026 (GLOBE NEWSWIRE) -- GraniteShares today announced the weekly distributions for its GraniteShares YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HO...
Artivion price target raised to $40 from $39 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on Artivion (AORT) to $40 from $39 and keeps a Buy rating on the shares. The firm updated its model following…
Artivion Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is driving double-digit revenue growth with a focus on high-margin aortic products, leveraging recent PMA approvals and acquisitions to solidify its pipeline. Strong Q2 results, robust On-X valve growth, and a disciplined R&D strategy support confidence in future free cash flow and margin expansion.
Artivion price target lowered to $39.20 from $42 at Ladenburg
Ladenburg lowered the firm’s price target on Artivion (AORT) to $39.20 from $42 and keeps a Buy rating on the shares following the Q2 report.
Artivion price target raised to $39 from $36 at Canaccord
Canaccord raised the firm’s price target on Artivion (AORT) to $39 from $36 and keeps a Buy rating on the shares. The firm said Artivion had an operationally productive quarter…
Artivion reports Q2 non-GAAP EPS 13c, consensus 10c
Reports Q2 revenue $125.8M, consensus $120.01M. “In Q2, we delivered 9% constant currency revenue growth and 7% adjusted EBITDA growth, reflecting continued execution of our strategy to drive long-ter...
Artivion repeats 2026 revenue $480M-$496M, consensus $486.23M
Sees 2026 adjusted EBITDA $92M-$99M.
Artivion Earnings Call Transcript: Q2 2026
Q2 2026 saw 9% revenue and 7% adjusted EBITDA growth, driven by On-X and stent grafts, with FDA PMA approval for AMDS and the Endospan acquisition expanding the aortic arch portfolio. Guidance for 2026 is reiterated, with strong outlook for AMDS and NEXUS launches.
Artivion Earnings release: Q2 2026
Artivion released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Artivion Slides: Q2 2026
Artivion has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Artivion Quarterly report: Q2 2026
Artivion has published its Q2 2026 quarterly earnings report on August 6, 2026.
Artivion Reports Second Quarter 2026 Financial Results
Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis an...
Artivion Slides: Investor presentation
Artivion has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Artivion to Participate in Upcoming Investor Conferences
ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i...
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results...
Artivion announces U.S. FDA approval of AMDS Hybrid Prosthesis
Artivion (AORT) announced that the U.S. FDA has approved the premarket approval application for the AMDS Hybrid Prosthesis. The approval covers acute Debakey Type I aortic dissections with either clin...
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration...
Artivion Transcript: Truist Securities MedTech Conference 2026
The company has built a leading aortic arch portfolio through acquisitions, targeting a $400 million U.S. market and $2 billion globally. AMDS and NEXUS launches are key near-term drivers, with PMA approvals and global expansion expected to accelerate growth.
Artivion to Participate in the 2026 Truist Securities MedTech Conference
ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2...
GraniteShares Announces Weekly Distributions for its YieldBOOST ETFs.
New York, June 04, 2026 (GLOBE NEWSWIRE) -- GraniteShares today announced the weekly distributions for its GraniteShares YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HO...
GraniteShares Announces Weekly Distributions for its YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HOYY, SMYY, BBYY, FBYY, IOYY, MAAY, NUGY, SEMY, QBY, RGYY, HMYY, RTYY, MUYY, TMYY, CWY, CRY and 20+ Others
New York, May 21, 2026 (GLOBE NEWSWIRE) -- GraniteShares today announced the weekly distributions for its GraniteShares YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HOY...
Endospan announces Artivion closed the transaction to acquire the company
Endospan announced that Artivion (AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration PMA approval of the NEXUS…
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction ...